Cannabinoid Agonists Inhibit Neuropathic Pain Induced by Brachial Plexus Avulsion in Mice by Affecting Glial Cells and MAP Kinases

Background Many studies have shown the antinociceptive effects of cannabinoid (CB) agonists in different models of pain. Herein, we have investigated their relevance in neuropathic pain induced by brachial plexus avulsion (BPA) in mice. Methodology/Principal Findings Mice underwent BPA or sham surgery. The mRNA levels and protein expression of CB 1 and CB 2 receptors were assessed by RT-PCR and immunohistochemistry, respectively. The activation of glial cells, MAP kinases and transcription factors were evaluated by immunohistochemistry. The antinociceptive properties induced by cannabinoid agonists were assessed on the 5 th and 30 th days after surgery. We observed a marked increase in CB 1 and CB 2 receptor mRNA and protein expression in the spinal cord and dorsal root ganglion, either at the 5 th or 30 th day after surgery. BPA also induced a marked activation of p38 and JNK MAP kinases (on the 30 th day), glial cells, such as microglia and astrocytes, and the transcription factors CREB and NF-κB (at the 5 th and 30 th days) in the spinal cord. Systemic treatment with cannabinoid agonists reduced mechanical allodynia on both the 5 th and 30 th days after surgery, but the greatest results were observed by using central routes of administration, especially at the 30 th day. Treatment with WIN 55,212-2 prevented the activation of both glial cells and MAP kinases, associated with an enhancement of CREB and NF-κB activation. Conclusions/Significance Our results indicate a relevant role for cannabinoid agonists in BPA, reinforcing their potential therapeutic relevance for the management of chronic pain states.